Over five years ago, the team behind FindMeCure, a UK-based patient-facing platform focused on clinical trial recruitment, began noticing a pattern – challenges with screening, enrolling, and retaining patients often due to deeper issues in trial planning. To address this upstream problem, they collaborated with feasibility and clinical operations experts to develop TrialHub – a platform designed to align with real-world workflows and deliver fast, automated access to critical trial planning data. By tackling the issue of fragmented, outdated, and incomplete information, TrialHub advances FindMeCure’s broader mission of bringing research closer to patients and improving the clinical trial ecosystem from the ground up.

TrialHub equips clinical trial planners with real-time, automated access to global research data and country-specific patient insights – helping reduce costly amendments, choose the right sites, and reach eligible patients at the right time. It is the first platform to fully automate Standard of Care research and, launching in 2025, the first to offer dynamic, country- and indication-specific Patient Journey Mapping. This transforms complex qualitative sources like medical guidelines and publications into clear, actionable data.

Most clinical trials fail because they target “unicorn patients” with strict eligibility criteria that don’t reflect real-world healthcare realities, overlooking patients’ true disease burden and motivations. According to Tufts Center for the Study of Drug Development, 57% of protocols face major amendments – 45% of which are avoidable – often due to unfeasible criteria and recruitment challenges. TrialHub helps prevent these issues by aligning trial design with actual patient experiences and local healthcare contexts, ensuring more realistic and successful recruitment.

TrialHub partners with leading pharmaceutical companies and clinical research organizations (CROs) across the industry to support smarter, faster clinical trial planning. The company focuses on three core areas: Trial Planning Data Intelligence, a $2 billion market helping teams make informed, data-driven decisions early in the process; Patient Feasibility Optimization Analytics, another $2 billion market focused on improving recruitment strategies through better patient insights; and End-to-End Drug Lifecycle Analytics, a $5 billion market aimed at enhancing decision-making across the full development journey.

TrialHub has experienced significant growth, securing partnerships with three of the world’s top 10 pharmaceutical companies and three leading global CROs. The platform delivers measurable business impact, including saving a top 5 CRO 171,000 man-hours in Standard of Care research, enabling a life sciences company to accelerate patient recruitment by threefold, and helping a top 10 pharmaceutical company achieve $1.6 million in cost savings within a single quarter. These results highlight TrialHub’s effectiveness in optimizing clinical trial efficiency and accelerating drug development.

Maya Zlatanova is the co-founder and CEO of TrialHub, where she leads across key areas including commercial strategy, product vision, and team culture. With over 15 years of global experience in clinical research regulations, patient recruitment, feasibility, and trial operations, she brings deep industry insight to the company. She is a recognized industry leader and frequent speaker at major healthcare events, known for her expertise in using technology to improve clinical trial design and patient engagement. Maya also serves on several industry committees and is passionate about advancing patient-centric approaches in clinical development.

DayOne spoke with Maya Zlatanova, co-founder and CEO of TrialHub and DayOne Accelerator Alumna 2023/24, about her journey with the DayOne Accelerator and what the future holds for the company. This is what she shared.

We discovered the DayOne Accelerator through two avenues. Firstly, I met Cecile, who was incredibly enthusiastic and passionate about life sciences, especially given her background as a former Pharma executive and as a patient advocate. Additionally, one of our advisors recommended the program, highlighting it as a great opportunity to join a cohort of companies at a similar stage. He emphasized the value of both receiving and offering mentorship, as well as helping advance life sciences.

What really stood out to us about the program was the people behind it – especially the mentors. Having access to experienced voices who are genuinely invested in your success is invaluable. One of the most critical aspects of early-stage growth is being able to validate your ideas and hypotheses quickly – and doing that alone can be time-consuming. Being part of a collaborative group that are open to sharing feedback, listening, and exchanging real-world experiences significantly accelerates that process. It creates a supportive environment where you can move faster and make decisions with more confidence. The DayOne Accelerator provided a valuable environment to validate our concepts and ultimately scale them into impactful solutions.

Throughout the program, every startup I met was truly inspiring. I especially appreciated that from day one at the kickoff bootcamp, there was a strong focus on how we communicated our story – our purpose and our “why.” It was a crucial aspect that’s often underestimated, and this emphasis proved both motivating and reaffirming as I continued through the program.

Following the program, we nearly doubled both our revenue and client base. It also supported our strategic planning for an exciting new offering – dynamic, country- and indication-specific Patient Journey Mapping, set to launch in the fall of 2025. We continue to stay connected with our mentors as well as several companies with whom we’ve established partnerships. We strongly recommend the program to new market entrants looking to optimize both their product and go-to-market strategy.

Our mission is clear: to bring clinical research closer to patients. Within the next five years, our ambitious goal is to ensure that every clinical trial, market access plan, and adoption strategy is fully aligned with the real-world experiences and needs of patients. We believe that true progress in healthcare depends on understanding the patient journey deeply and integrating that insight into every stage of drug development and delivery.

To achieve this vision, TrialHub combines rich, high-quality data, deep industry expertise, and cutting-edge technology. Our unique approach makes us the ideal partner for pharmaceutical companies, CROs, and healthcare stakeholders aiming to design and execute research that is not only scientifically rigorous but also patient-centered and practical. By bridging the gap between research and patient realities, we strive to accelerate the development of treatments that are more accessible, effective, and aligned with the needs of those they serve.

Every day a trial is delayed is a day lost for a patient waiting on treatment.